Suppr超能文献

神经肿瘤学与放射基因组学:是时候整合了吗?

Neuro-Oncology and Radiogenomics: Time to Integrate?

机构信息

From the Department of Cancer Imaging (A.L.)

Sir Peter MacCallum Department of Oncology (A.L.).

出版信息

AJNR Am J Neuroradiol. 2020 Nov;41(11):1982-1988. doi: 10.3174/ajnr.A6769. Epub 2020 Sep 10.

Abstract

Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.

摘要

放射组学旨在基于影像学特征预测遗传标志物。分子标志物在颅内神经胶质瘤的诊断和治疗中的关键重要性促使放射组学研究迅速发展,其复杂性也逐渐增加。尽管所检查的技术取得了进展,但很少有转化为临床领域。这导致了前沿研究与临床实践之间的脱节日益严重,尽管其根本目标是这些技术能够改善患者的护理。因此,本综述的目的是讨论放射组学可能有助于患者管理的可能临床情况。这包括为患者咨询提供便利、在无法进行完整分子特征分析时确定最佳患者管理、对肿瘤进行重新分类以及克服组织学评估的一些局限性。该综述还讨论了根据临床情况选择相关放射组学特征的注意事项。

相似文献

1
Neuro-Oncology and Radiogenomics: Time to Integrate?
AJNR Am J Neuroradiol. 2020 Nov;41(11):1982-1988. doi: 10.3174/ajnr.A6769. Epub 2020 Sep 10.
2
From K-space to Nucleotide: Insights Into the Radiogenomics of Brain Tumors.
Top Magn Reson Imaging. 2017 Feb;26(1):33-41. doi: 10.1097/RMR.0000000000000114.
3
Pediatric Brain Tumor Genetics: What Radiologists Need to Know.
Radiographics. 2018 Nov-Dec;38(7):2102-2122. doi: 10.1148/rg.2018180109.
4
Radiomics, Metabolic, and Molecular MRI for Brain Tumors.
Semin Neurol. 2018 Feb;38(1):32-40. doi: 10.1055/s-0037-1618600. Epub 2018 Mar 16.
5
Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review.
Br J Radiol. 2018 Dec;91(1092):20170930. doi: 10.1259/bjr.20170930. Epub 2018 Jun 29.
6
Progress in neuro-imaging of brain tumors.
Curr Opin Oncol. 2016 Nov;28(6):484-493. doi: 10.1097/CCO.0000000000000328.
7
Neuroimaging and genetic influence in treating brain neoplasms.
Neuroimaging Clin N Am. 2015 Feb;25(1):121-40. doi: 10.1016/j.nic.2014.09.011.
8
Radiogenomics of Gliomas.
Radiol Clin North Am. 2021 May;59(3):441-455. doi: 10.1016/j.rcl.2021.02.002.
9
Radiogenomics and IR.
J Vasc Interv Radiol. 2018 May;29(5):706-713. doi: 10.1016/j.jvir.2017.11.021. Epub 2018 Mar 15.
10
Imaging genomics of Glioblastoma: state of the art bridge between genomics and neuroradiology.
Neuroimaging Clin N Am. 2015 Feb;25(1):141-53. doi: 10.1016/j.nic.2014.09.010.

引用本文的文献

1
Evolution of Molecular Biomarkers and Precision Molecular Therapeutic Strategies in Glioblastoma.
Cancers (Basel). 2024 Oct 29;16(21):3635. doi: 10.3390/cancers16213635.
2
Reply.
AJNR Am J Neuroradiol. 2024 Jul 8;45(7):E23. doi: 10.3174/ajnr.A8347.
5
The T2-FLAIR mismatch sign in oncologic neuroradiology: History, current use, emerging data, and future directions.
Neuroradiol J. 2024 Aug;37(4):441-453. doi: 10.1177/19714009231212375. Epub 2023 Nov 4.
6
Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
AJNR Am J Neuroradiol. 2023 Nov;44(11):1270-1274. doi: 10.3174/ajnr.A8034. Epub 2023 Oct 26.
7
Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Neuroradiology. 2023 Aug;65(8):1215-1223. doi: 10.1007/s00234-023-03175-0. Epub 2023 Jun 15.
10
Spatially coherent modeling of 3D FDG-PET data for assessment of intratumoral heterogeneity and uptake gradients.
J Med Imaging (Bellingham). 2022 Jul;9(4):045003. doi: 10.1117/1.JMI.9.4.045003. Epub 2022 Jul 29.

本文引用的文献

1
Isocitrate Dehydrogenase Mutations in Glioma: From Basic Discovery to Therapeutics Development.
Front Oncol. 2019 Jun 12;9:506. doi: 10.3389/fonc.2019.00506. eCollection 2019.
2
Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research.
AJNR Am J Neuroradiol. 2019 May;40(5):758-765. doi: 10.3174/ajnr.A6025. Epub 2019 Apr 4.
4
Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in -Mutant Lower Grade Gliomas.
AJNR Am J Neuroradiol. 2019 Mar;40(3):426-432. doi: 10.3174/ajnr.A5957. Epub 2019 Jan 31.
5
Emerging Applications of Artificial Intelligence in Neuro-Oncology.
Radiology. 2019 Mar;290(3):607-618. doi: 10.1148/radiol.2018181928. Epub 2019 Jan 22.
6
F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
Ann Nucl Med. 2019 Apr;33(4):295-302. doi: 10.1007/s12149-018-01328-3. Epub 2019 Jan 3.
7
There is an exception to every rule-T2-FLAIR mismatch sign in gliomas.
Neuroradiology. 2019 Feb;61(2):225-227. doi: 10.1007/s00234-018-2148-4. Epub 2018 Dec 18.
8
10
Diffuse low-grade glioma, oncological outcome and quality of life: a surgical perspective.
Curr Opin Oncol. 2018 Nov;30(6):383-389. doi: 10.1097/CCO.0000000000000483.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验